Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.47 |
| ▸ | HTR2C | P28335 | 11/20 | 0.47 |
| ▸ | HTR2B | P41595 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 2/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | APOB | P04114 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644576 | 0.89 | EIF2AK3 (0.45) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6646859 | 0.87 | LMNA (0.47) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6647710 | 0.86 | EIF2AK3 (0.47) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6645134 | 0.85 | HTR2A (0.53) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6665020 | 0.84 | HTR2A (0.44) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6646377 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6643318 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6809846 | 0.84 | MTTP (0.52) | HTR2AHTR2CHTR2BEIF2AK3MTTP | |
| SCHEMBL6664596 | 0.83 | EIF2AK3 (0.47) | HTR2AHTR2CHTR2BLMNATP53 | |
| SCHEMBL6648674 | 0.82 | EIF2AK3 (0.45) | HTR2AHTR2CHTR2BLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | HTR2A 855/4885HTR2C 1349/4885HTR2B 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.